Oculis Holding AG (NASDAQ:OCS - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $22.01 and last traded at $22.01, with a volume of 21511 shares traded. The stock had previously closed at $21.15.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on OCS shares. Chardan Capital restated a "buy" rating and issued a $28.00 target price on shares of Oculis in a report on Tuesday, January 7th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Oculis in a research note on Monday, January 6th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $28.80.
Read Our Latest Stock Analysis on Oculis
Oculis Stock Up 5.8 %
The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $16.48 and a two-hundred day simple moving average of $14.00. The company has a market capitalization of $906.48 million, a PE ratio of -11.60 and a beta of -0.33.
Oculis Company Profile
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Further Reading
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
